Tuesday January 16th 2018

Administration of leukemia inhibitory factor increases Opalin and myelin oligodendrocyte glycoprotein expression in the cerebral cortex in a…

Authors: Mashayekhi F, Hadiyan SP, Salehi Z Abstract Multiple sclerosis (MS) lesions are characterized by inflammatory demyelination and reactive gliosis, and although remyelination occurs in some lesions it is limited and incomplete. Leukemia inhibitory factor (LIF) is an important cytokine that stimulates oligodendrocyte proliferation and survival in vitro. Opalin is a unique molecular marker for mature oligodendrocytes. The aim of this study was to demonstrate the role of LIF on Opalin and myelin oligodendrocyte glycoprotein (MOG) expression in the cerebral cortex of cuprizone-induced MS mice. The mice were treated with cuprizone for five weeks in order to induce MS. The mice were then divided into 3 groups. The first group was injected intraperitoneally (IP) with LIF for six we…

Read article here:  

Administration of leukemia inhibitory factor increases Opalin and myelin oligodendrocyte glycoprotein expression in the cerebral cortex in a…

Leave a Comment

More from category

FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS
FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS

The FDA responded to a petition, saying that after reviewing the evidence, there is no basis for the claim that vitamin [Read More]

Effects of sport climbing on multiple sclerosis – Steimer J, Weissert R.
Effects of sport climbing on multiple sclerosis – Steimer J, Weissert R.

Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease of the central nervous system (CNS) with [Read More]

Researchers use novel PET tracer to assess myelin damage in mouse models of MS
Researchers use novel PET tracer to assess myelin damage in mouse models of MS

The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallmark of the [Read More]

MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe
MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe

The European Commission clears the anti-CD20 monoclonal antibody for adults with relapsing multiple sclerosis and early [Read More]

New PET radiotracer offers insight into multiple sclerosis
New PET radiotracer offers insight into multiple sclerosis

Combining PET scans with a novel radiotracer could help researchers track damage...Read more on AuntMinnie.comRelated [Read More]